Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp RVXCF


Primary Symbol: T.RVX

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Comment by pricelesson Jan 17, 2022 10:28am
155 Views
Post# 34324113

RE:RE:RE:RE:RE:RE:Interference

RE:RE:RE:RE:RE:RE:InterferenceQT,

yes I listened to the Dec webcast and CC, and someone on the RVX  Covid cliical advisory team has been on CNN numerous times in the past few year.  IMO  RVX needs a BP partnership to get the market respect  for valuation .  Everything RVX has tried has not worked even after numrous fantastic peer reviwed publications on several indications plus EVersana partnership , plus the FDA  BTD , plus just the Covid trial angle, has failed to attract new investors and a higher market cap valuation,   I hate to say it but i wish RVX would take BP partnership approach rather than stand  alone  on their own approach,  RVX just doesn't have the continued  finanacial resources to make it happen ONly a large  BP or maybe a huge private equity firm . Maybe, If RVX get the media war room /PR with good inital Coivd  results we can get to a point where institutional funds can start getting plowing money in other tahn Hepalink,  BTW where is  the African gold that was suppose to sail in 
<< Previous
Bullboard Posts
Next >>